Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells

被引:26
|
作者
Xu, Gui-Li [1 ]
Ni, Cai-Fang [1 ]
Liang, Han-Si [2 ]
Xu, Yun-Hua [1 ]
Wang, Wan-Sheng [1 ]
Shen, Jian [1 ]
Li, Ming-Ming [1 ]
Zhu, Xiao-Li [1 ]
机构
[1] Soochow Univ, Dept Intervent Radiol, Affiliated Hosp 1, 188 Shizi Rd, Suzhou 215006, Jiangsu, Peoples R China
[2] Soochow Univ, Jiangsu Inst Clin Immunol, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China
来源
GASTROENTEROLOGY REPORT | 2020年 / 8卷 / 05期
关键词
programmed death-1 ligand 1 (PD-L1); sorafenib-resistant hepatocellular carcinoma (HCC) cells; epithelial-to-mesenchymal transition (EMT); DRUG-RESISTANCE; PROGNOSTIC ROLE; TUMOR-GROWTH; CANCER; CHEMORESISTANCE; EMT; OVEREXPRESSION; CONTRIBUTES; METASTASIS; ACTIVATION;
D O I
10.1093/gastro/goaa049
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The epithelial-to-mesenchymal transition (EMT) status is associated with programmed death-1 ligand 1 (PD-L1) expression in various cancers. However, the role and molecular mechanism of PD-L1 in the EMT of sorafenib-resistant hepatocellular carcinoma (HCC) cells remain elusive. In this study, we aimed to investigate the regulation of PD-L1 on the EMT in sorafenib-resistant HCC cells. Methods: Initially, the sorafenib-resistant HCC cell lines HepG2 SR and Huh7 SR were established. Western-blot assays were used to detect the expression of PD-L1, E-cadherin, and N-cadherin. The intervention and overexpression of PD-L1 were used to explore the role of PD-L1 in the regulation of EMT in HepG2 SR and Huh7 SR cells. Cell migration and invasion were assessed by transwell assays. PD-L1 or Sterol regulatory element-binding protein 1 (SREBP-1) overexpression and knock-down were performed in order to study the mechanism of PD-L1 in sorafenib-resistant HCC cells. Results: PD-L1 expression was upregulated, whereas E-cadherin levels were downregulated and N-cadherin expression was increased in HepG2 SR and Huh7 SR cells. The cell viabilities of HepG2 and Huh7 cells were lower than those of HepG2 SR and Huh7 SR cells. PD-L1 overexpression reduced E-cadherin expression and increased N-cadherin levels, whereas PD-L1 knock-down increased E-cadherin expression and decreased N-cadherin expression. PD-L1 expression promoted EMT and the migratory and invasive abilities of HepG2 SR and Huh7 SR cells. PD-L1 promoted the EMT of sorafenib-resistant HCC cells via the PI3K/Akt pathway by activating SREBP-1 expression in HepG2 SR and Huh7 SR cells. Conclusions: The findings reveal that PD-L1 expression promotes EMT of sorafenib-resistant HCC cells.
引用
收藏
页码:390 / 398
页数:9
相关论文
共 50 条
  • [21] Upregulation of H19 promotes invasion and induces epithelial-to-mesenchymal transition in esophageal cancer
    Huang, Cheng
    Cao, Lihua
    Qiu, Limin
    Dai, Xiaoli
    Ma, Linwei
    Zhou, Yingting
    Li, Huifen
    Gao, Min
    Li, Weiyong
    Zhang, Qing
    Han, Koulan
    Lv, Hongzhen
    ONCOLOGY LETTERS, 2015, 10 (01) : 291 - 296
  • [22] Delphinidin inhibits epidermal growth factor-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma cells
    Lim, Won-Chul
    Kim, Hyunhee
    Ko, Hyeonseok
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (06) : 9887 - 9899
  • [23] HBx Modulates Drug Resistance of Sorafenib-Resistant Hepatocellular Carcinoma Cells
    Liu, Yaping
    Liu, Xu
    Luo, Miaosha
    Li, Yarui
    Li, Hongxia
    DISCOVERY MEDICINE, 2023, 35 (179) : 1035 - 1042
  • [24] ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition
    Xu, Tao
    Zhang, Jian
    Chen, Wei
    Pan, Shengjing
    Zhi, Xiao
    Wen, Liang
    Zhou, Yue
    Chen, Bryan Wei
    Qiu, Junyu
    Zhang, Yun
    Yang, Qi
    Feng, Xinhua
    Bai, Xueli
    Liang, Tingbo
    CANCER LETTERS, 2016, 377 (02) : 140 - 148
  • [25] PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
    Ock, Chan-Young
    Kim, Sehui
    Keam, Bhumsuk
    Kim, Miso
    Kim, Tae Min
    Kim, Jin-Ho
    Jeon, Yoon Kyung
    Lee, Ju-Seog
    Kwon, Seong Keun
    Hah, J. Hun
    Kwon, Tack-Kyun
    Kim, Dong-Wan
    Wu, Hong-Gyun
    Sung, Myung-Whun
    Heo, Dae Seog
    ONCOTARGET, 2016, 7 (13) : 15901 - 15914
  • [26] PLK1 promotes epithelial-mesenchymal transition and metastasis of gastric carcinoma cells
    Cai, Xiao Peng
    Chen, Liang Dong
    Song, Hai Bin
    Zhang, Chun Xiao
    Yuan, Ze Wei
    Xiang, Xian
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (10): : 4172 - 4183
  • [27] Clinical implication of Frizzled 2 expression and its association with epithelial-to-mesenchymal transition in hepatocellular carcinoma
    Asano, Tomonari
    Yamada, Suguru
    Fuchs, Bryan C.
    Takami, Hideki
    Hayashi, Masamichi
    Sugimoto, Hiroyuki
    Fujii, Tsutomu
    Tanabe, Kenneth K.
    Kodera, Yasuhiro
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 50 (05) : 1647 - 1654
  • [28] Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer
    Aghajani, Marra Jai
    Yang, Tao
    Schmitz, Ulf
    James, Alexander
    McCafferty, Charles Eugenio
    de Souza, Paul
    Niles, Navin
    Roberts, Tara L.
    ENDOCRINE CONNECTIONS, 2020, 9 (10): : 1028 - 1041
  • [29] Ascochlorin Enhances the Sensitivity of Doxorubicin Leading to the Reversal of Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma
    Dai, Xiaoyun
    Ahn, Kwang Seok
    Wang, Ling Zhi
    Kim, Chulwon
    Deivasigamni, Amudha
    Arfuso, Frank
    Um, Jae-Young
    Kumar, Alan Prem
    Chang, Young-Chae
    Kumar, Dhiraj
    Kundu, Gopal C.
    Magae, Junji
    Goh, Boon Cher
    Hui, Kam Man
    Sethi, Gautam
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (12) : 2966 - 2976
  • [30] Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells
    Li, Dong
    Sun, Fei-fan
    Wang, Dan
    Wang, Tao
    Peng, Jing-jing
    Feng, Jian-Qiong
    Li, Hua
    Wang, Chao
    Zhou, Dai-jun
    Luo, Hong
    Fu, Zeng-qiang
    Zhang, Tao
    ONCOLOGY RESEARCH, 2020, 28 (05) : 467 - 481